Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)

Journal of Clinical Oncology

Volumn 1, Issue 2, 1983, Pages 91-98

  Skarin, A T ^a   Canellos, G P ^a   Rosenthal, D S ^a   Case, D C ^b   MacIntyre, J M ^b   Pinkus, G S ^b   Moloney, W C ^b   Frei, E ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; VINCRISTINE; VINCRISTINE SULFATE;

ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW DEPRESSION; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; DRUG THERAPY; HEART; HEART FAILURE; HUMAN; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LUNG TOXICITY; LYMPHATIC SYSTEM; LYMPHOHISTIOCYTOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NERVOUS SYSTEM; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; RASH; RESPIRATORY SYSTEM; SKIN TOXICITY; THERAPY; TUMOR REGRESSION;

EID: 0021088267     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1983.1.2.91     Document Type: Article

References (0)